SHZ · 002412.SZ
Hunan Hansen Pharmaceutical Co., Ltd.
CN¥7.48+CN¥0.03 (+0.4%)
Hunan Hansen Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
Loading market information…
SHZ · 002788.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Luyan Pharma Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 66.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Luyan Pharma Co.,Ltd.’s forward annual dividend is CN¥0.35 per share, paid annual. The forward yield is 3.73% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Luyan Pharma Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Luyan Pharma Co.,Ltd. is a Chinese enterprise dedicated to the complete lifecycle of human health products, from their initial research and development through manufacturing and ultimate market distribution. Additionally, the company manages its own pharmaceutical distribution channels and a network of direct retail pharmacies. Originally established as Luyan (Fujian) Pharma Co. Ltd., the firm rebranded and adopted its current name, Luyan Pharma Co.,Ltd., in June 2016. This company was founded in 1992 and maintains its principal offices in Xiamen, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥7.48+CN¥0.03 (+0.4%)
Hunan Hansen Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
CN¥2.72-CN¥0.03 (-1.09%)
Realcan Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.0% below the high.
CN¥12.13-CN¥0.14 (-1.14%)
Guangdong Transtek Medical Electronics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.92% below the high.
CN¥19.41-CN¥0.09 (-0.46%)
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd’s quoted price sits in the lower half of its reported 52-week range, 41.15% below the high.
CN¥5.05-CN¥0.23 (-4.36%)
Shanghai Kehua Bio-engineering Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.02% below the high.
CN¥2.93-CN¥0.06 (-2.01%)
Shenzhen Glory Medical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.07% below the high.
CN¥15.51+CN¥0.29 (+1.91%)
Jianzhijia Pharmaceutical Chain Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.45% below the high.
CN¥5.69-CN¥0.18 (-3.07%)
Chemclin Diagnostics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.45% below the high.
